Protalix Biotherapeutics Inc (PLX) support and resistance · P/E 31, rev $53.6M
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
This page maps Protalix Biotherapeutics Inc (PLX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported PLX revenue for 2026-06-30 was $53.6M. Net income was $22.1M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
PLX currently screens at market cap $122.6M and trailing P/E 30.8. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new PLX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the PLX quote page for the session range and the stock page for the full model.
Not investment advice.